Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.38 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.38 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.38 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26548503 | 0.94 | ALB (0.41) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL19929588 | 0.88 | PLAAT3 (0.40) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL22022014 | 0.88 | PLAAT3 (0.45) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL19929582 | 0.88 | FOLH1 (0.41) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL19929581 | 0.88 | CA12 (0.39) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL19933029 | 0.88 | ALB (0.49) | CA12CA1CA2CA9ALB | |
| SCHEMBL19929585 | 0.88 | HPGD (0.49) | ALBOTCSLC5A1HPGD | |
| SCHEMBL19929563 | 0.85 | SIRT2 (0.40) | SIRT2SIRT1ALBHPGD | |
| SCHEMBL22021340 | 0.84 | ALB (0.45) | ALBOTCGRIK1 | |
| SCHEMBL19929580 | 0.84 | ALB (0.53) | ALBSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | CA12 3060/4885CA1 3526/4885CA2 4786/4885 |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | CA12 3060/4885CA1 3526/4885CA2 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.